Department of Anaesthesiology and Intensive Care Medicine, University Medical Centre Schleswig-Holstein, Campus Kiel, Kiel, Germany.
Division of Mucosal Immunology and Diagnostic, Research Centre Borstel, Leibniz-Centre for Medicine and Biosciences, Borstel, Germany.
Sci Rep. 2017 Oct 17;7(1):13382. doi: 10.1038/s41598-017-13850-x.
Capillary leakage syndrome, vasomotor disturbances and gut atony are common clinical problems in intensive care medicine. Various inflammatory mediators and signalling pathways are involved in these pathophysiological alterations among them platelet-activating factor (PAF). The related signalling mechanisms of the PAF-induced dysfunctions are only poorly understood. Here we used the model of the isolated perfused rat small intestine to analyse the role of calcium (using calcium deprivation, IP-receptor blockade (2-APB)), cAMP (PDE-inhibition plus AC activator), myosin light chain kinase (inhibitor ML-7) and Rho-kinase (inhibitor Y27632) in the following PAF-induced malfunctions: vasoconstriction, capillary and mucosal leakage, oedema formation, malabsorption and atony. Among these, the PAF-induced vasoconstriction and hyperpermeability appear to be governed by similar mechanisms that involve IP3 receptors, extracellular calcium and the Rho-kinase. Our findings further suggest that cAMP-elevating treatments - while effective against hypertension and oedema - bear the risk of dysmotility and reduced nutrient uptake. Agents such as 2-APB or Y27632, on the other hand, showed no negative side effects and improved most of the PAF-induced malfunctions suggesting that their therapeutic usefulness should be explored.
毛细血管渗漏综合征、血管舒缩功能紊乱和肠道弛缓是重症监护医学中的常见临床问题。各种炎症介质和信号通路参与了这些病理生理改变,其中血小板激活因子 (PAF) 就是其中之一。PAF 诱导的功能障碍的相关信号机制了解甚少。在这里,我们使用分离的灌注大鼠小肠模型来分析钙(使用钙剥夺、IP 受体阻断(2-APB))、cAMP(PDE 抑制加 AC 激活剂)、肌球蛋白轻链激酶(抑制剂 ML-7)和 Rho-激酶(抑制剂 Y27632)在以下 PAF 诱导的功能障碍中的作用:血管收缩、毛细血管和粘膜渗漏、水肿形成、吸收不良和弛缓。在这些功能障碍中,PAF 诱导的血管收缩和高通透性似乎受涉及 IP3 受体、细胞外钙和 Rho 激酶的类似机制控制。我们的研究结果进一步表明,虽然升高 cAMP 的治疗方法对高血压和水肿有效,但存在运动障碍和营养吸收减少的风险。另一方面,像 2-APB 或 Y27632 这样的药物没有副作用,并且改善了大多数 PAF 诱导的功能障碍,这表明应该探索它们的治疗用途。